Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Clinical Trail of Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer

NCT03371693 is registered in ClinicalTrials.gov with Zhongnan Hospital as lead sponsor.

NCT NCT03371693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03371693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Clinical Trail of Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
Lead sponsor
Zhongnan Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2017
Completion date
March 30, 2023
Enrollment
112 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, hyperthermic intraperitoneal chemotherapy(hipec), ovarian cancer, ovarian cancer, epithelial, ovarian neoplasms, ovary neoplasm